Comment by George Scangos ( CEO / Biogen Idec ) during Biogen Idec's Earnings Report today, quote,
" During the last 12 months, our improved focus and reinvigoration of the organization has driven strong product performance and allowed our late stage pipeline to mature. Francesco and Doug will talk about these in greater depth.
But to highlight, after tremendous work by many people in the organization, we received a new label for TYSABRI in the EU to include JC Virus Antibody Status as an additional risk factor for PML. Physicians and Patients can now consider JCV Antibody Status, as well as prior immunosuppressant use and treatment duration when assessing the risk of PML for individual patients.
Along with the commercial availability of the JCV Assay in Europe, the MS community now has more tools to make an informed treatment decision, which we all believe will unlock the value of TYSABRI. Concurrently, the European Commission renewed the 5- year marketing authorization for TYSABRI.
The impressive growth of the TYSABRI business over this past year and the strong demand we've seen this quarter is a testament to the efficacy of TYSABRI, as well as the excellent planning and execution."
.....of course then he goes on to mention AVONEX
Should turn out to be a most interesting Quarter for Elan.
they also went into some detailed numbers.....some highlights...
the run rate for Tysabri is now $ 1.5 Billion in annualized in-market sales.
Q2 was very strong ....revenue @ $ 389 million, an increase of 31 % vs. the same quarter last year......
ended the quarter with 61,500 patients an increase of 2,400 over last quarter,......reached milestone with TYSABRI..... 1 million infusions since relaunch in 2006
